Last reviewed · How we verify
Regular nasal air
Regular nasal air is a Small molecule drug developed by Region Skane. It is currently in Phase 2 development.
Regular nasal air is studied in various clinical trials for conditions such as asthma, dysfunctional voiding, type 1 diabetes, obstructive sleep apnea, and high altitude pulmonary hypertension. The interventions used in these trials include alternative nostril breathing technique, Buteyko breathing, and diaphragmatic breathing, but the modality of regular nasal air itself remains unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Regular nasal air |
|---|---|
| Sponsor | Region Skane |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) (NA)
- Nasal High-Flow in COPD (NA)
- Comparative Effects of Blow Bottle and Acapella Along With Diaphragmatic Breathing in Patients With Pneumonia (NA)
- The Role of the Device Operating Under the Continuous Positive Airway Pressure in the Recovery Process of Cochlea (NA)
- Breathing for Adolescent Stress Reduction Feasibility RCT (NA)
- Diaphragmatic Breathing Exercises and Pelvic Floor Retraining in Children With Dysfunctional Voiding (NA)
- IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regular nasal air CI brief — competitive landscape report
- Regular nasal air updates RSS · CI watch RSS
- Region Skane portfolio CI
Frequently asked questions about Regular nasal air
What is Regular nasal air?
Who makes Regular nasal air?
What development phase is Regular nasal air in?
Related
- Manufacturer: Region Skane — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing